SpineGuard Announces Its 2024 Financial Calendar

Regulatory News:

SpineGuard (FR0011464452 – ALSGD) (Paris:ALSGD), an innovative company that deploys its DSG (Dynamic Surgical Guidance) sensing technology to secure and streamline the placement of bone implants, announced today its schedule for the publication of financial information for 2024.

2024 financial calendar

Event	Date*
2023 Full-Year Sales	January 10, 2024
2023 Full-Year Results	April 17, 2024
2024 First-Quarter Sales	April 17, 2024
Annual Shareholders Meeting	June 5, 2024 (1st summoning) June 26, 2024 (2nd summoning if required)
2024 First-Half Sales	July 10, 2024
2024 First-Half Results	September 11, 2024
2024 Third-Quarter Sales	October 9, 2024

Note (*): Press releases are published after stock market closes. This information is subject to modification.

About SpineGuard

Founded in 2009 in France and the USA by Pierre Jérôme and Stéphane Bette, SpineGuard is an innovative company deploying its proprietary radiation-free real time sensing technology DSG (Dynamic Surgical Guidance) to secure and streamline the placement of implants in the skeleton. SpineGuard designs, develops and markets medical devices embedding its technology. Over 95,000 surgical procedures have been secured worldwide thanks to DSG and 29 studies published in peer-reviewed scientific journals have demonstrated the multiple benefits DSG offers to patients, surgeons, surgical staff and hospitals. Building on these strong fundamentals and several strategic partnerships, SpineGuard is expanding the scope of its DSG technology to the treatment of scoliosis via anterior approach, sacroiliac joint fusion, dental implantology and innovations such as the « smart » pedicle screw and power drill or surgical robotics. DSG was co-invented by Maurice Bourlion, Ph.D., Ciaran Bolger, M.D., Ph.D., and Alain Vanquaethem, Biomedical Engineer. SpineGuard has engaged in multiple ESG initiatives.

For further information, visit www.spineguard.com

Disclaimer

The SpineGuard securities may not be offered or sold in the United States as they have not been and will not be registered under the Securities Act or any United States state securities laws, and SpineGuard does not intend to make a public offer of its securities in the United States. This is an announcement and not a prospectus, and the information contained herein does and shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of the securities referred to herein in the United States in which such offer, solicitation or sale would be unlawful prior to registration or exemption from registration.

View source version on businesswire.com: https://www.businesswire.com/news/home/20231220007523/en/

The Spineguard Stock at the time of publication of the news with a raise of +1,44 % to 0,207EUR on Lang & Schwarz stock exchange (20. Dezember 2023, 17:28 Uhr).